Olga S. Voznesensky

The paper examines immune infiltration in prostate cancer, finding higher T-cell density correlates with reduced CD8 effector cells and increased TIGIT, suggesting immune suppression.

This paper identifies FOXJ1 as a mediator of taxane resistance in prostate cancer by regulating microtubule dynamics, with clinical implications for patient stratification.

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

This study shows that ARv7 drives AR activity in castration-resistant prostate cancer through increased chromatin accessibility mediated by NFI factors.

The paper shows that ctDNA is undetectable in localized prostate cancer but present in metastatic cases, suggesting lower dissemination and detectability in early stages.